APVO - Company ID 0001671584
The table below shows Aptevo Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $3.92M | $4.04M | $3.33M | $3.63M | $3.10M | $3.64M |
| SG&A |
Aptevo Therapeutics Inc. reported annual revenue of $3.11M for fiscal year 2022. That is down 74.7% from $12.29M in fiscal 2021. Over the 8 fiscal years shown, annual revenue declined from $33.60M (FY 2015) to $3.11M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.91M |
| $3.57M |
| $2.90M |
| $2.85M |
| $2.11M |
| $2.38M |
| Operating income | -$6.84M | -$7.61M | -$6.23M | -$6.48M | -$5.21M | -$6.02M |
| Income tax | - | - | - | - | - | - |
| Net income | -$6.70M | -$7.55M | -$6.20M | -$6.41M | -$5.10M | -$5.88M |
| EPS (diluted) | -$6.41 | -$2.23 | -$8.40 | -$1.58K | -$357.86 | -$1.24K |